Anti-p-PTEN (Tyr240) Antibody, clone 3G6 ZooMAb® Rabbit Monoclonal

Description

• General description: We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.
• Specificity: Clone 3G6 is a ZooMAb® rabbit recombinant monoclonal antibody that specifically detects PTEN. It targets an epitope surrounding phosphotyrosine 240.
• Immunogen: BSA-conjugated linear peptide corresponding to 17 amino acids surrounding phosphotyrosine 240 from the C-terminal half of human PTEN.
• Application: Quality Control Testing Evaluated by Immunohistochemistry (Paraffin) in human astrocytoma tissue sections.Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution of this antibody detected PTEN phosphorylated on tyrosine 240 in human astrocytoma tissue sections. Tested applicationsImmunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected PTEN phosphorylated on tyrosine 240 in normal human brain tissue sections.Immunohistochemistry Applications: A representative lot detected PTEN phosphorylated on tyrosine 240 in Immunohistochemistry applications (Ma, J., et. al. (2019). Cancer Cell. 35(3):504-518).Affinity Binding Assay: A representative lot of this antibody bound phopho-PTEN (Tyr240) peptide with a KD of 1.0 x 10-12 in an affinity binding assay.Western Blotting Analysis: A 1:10,000 dilution from a representative lot detected wild-type PTEN, but not the mutant PTEN.Western Blotting Analysis: A representative lot detected PTEN phosphorylated on tyrosine 240 in Western Blotting applications (Ma, J., et. al. (2019). Cancer Cell. 35(3):504-518).Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user
• Target description: Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (UniProt: P60484; also known as Mutated in multiple advanced cancers 1, Phosphatase and tensin homolog) is encoded by the PTEN (also known as MMAC1, TEP1) gene (Gene ID: 5728) in human. PTEN belongs to the family of lipid phosphatases. It contains an N-terminal phosphatase catalytic domain, a C2-domain that binds to phospholipid membranes, and a C-terminal regulatory tail. It is a dual-specific phosphatase, which dephosphorylates both lipid and protein substrates. PTEN suppresses the activity of a major cell proliferation pathway in the cytoplasm; as such, its absence or functional deficiency is associated with tumor growth. PTEN blocks the phosphatidylinositol 3-kinase/Akt signaling pathway by removing the phosphate in the 3-position on phosphoinositide-3, 4, 5-trisphosphate (PIP3). Dephosphorylation of PIP3 is an important factor in cell growth, proliferation, apoptosis, and survival. Dephosphorylation of PIP3 blocks Akt signaling that can lead to higher activity of pro-apoptotic molecules such as Bad and Caspase-9. PTEN activity, stability, localization, and conformation are controlled through complex regulatory mechanisms, including the reversible phosphorylation of several Serine/Threonine residues in its unfolded C-terminal tail region (PTEN-C-tail, residues 351-403). Alternative translation of PTEN is reported to encode a 576-amino acid translational variant that is known as PTEN-Long with a 173-amino acid domain at its N-terminus followed by the classical 403 amino acids of PTEN. PTEN-Long is a membrane permeable, secreted protein that can enter other cells and acts as an antagonist of the PI3K pathway. PTEN is considered a major tumor suppressor and its mutations are reported in several human tumors. Over seventy different types of PTEN mutation have been recorded in patients with Cowden syndrome. PTEN -/- mice exhibit higher levels of 3 -phosphorylated phospholipids and die during embryogenesis due to the failure of developmental apoptosis. This ZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Ferrarelli, LK., et al. (2019). Sci. Signal 16(577); eaax6492; Hopkins, BD., et al. (2013). Science. 341(6144); 399-402).
• Physical form: Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.
• Reconstitution: 300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
• Storage and Stability: Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
• Legal Information: ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.